RNA Sequencing Analysis of NCAPD2 Knockdown in Lung Adenocarcinoma Cell Line PC9

This study investigates the effect of NCAPD2 knockdown on lung adenocarcinoma (LUAD) by performing RNA sequencing on PC9 cell lines. The experiment included three control PC9 cells and three PC9 cells in which NCAPD2 was knocked down using shRNA. This RNA sequencing experiment aims to elucidate the role of NCAPD2 in regulating gene expression associated with tumor proliferation, migration, and survival in LUAD. Analysis of differential gene expression provides insights into the pathways affected by NCAPD2 knockdown, with an emphasis on signaling pathways critical to LUAD progression, such as the PI3K/AKT pathway. Overall design: The experimental design involved RNA sequencing of the lung adenocarcinoma cell line PC9, with the following groups: (1) three control PC9 cell replicates (shNC) and (2) three PC9 cell replicates with NCAPD2 knockdown (shRNA). Total RNA was extracted from each sample, and the quality was verified before sequencing library preparation. Sequencing was conducted using an Illumina platform to generate high-quality reads for transcriptome analysis. Differential expression analysis was performed to compare gene expression between the control and knockdown groups. The objective was to assess the impact of NCAPD2 knockdown on the transcriptional landscape of PC9 cells and identify affected pathways.